Abstract
Ovarian cancer peritoneal carcinomatosis requires a multimodal-treatment approach. Current treatment considerations are analyzed in this update and include the management of recurrent malignant ascites and the understanding of its pathophysiology, the role of peritoneal washing cytology in detecting peritoneal metastases, capsular invasion and ovarian cancer histologic type, interpretation of pretreatment Ca-125 levels at different time points of ovarian cancer therapeutic management, characteristics of 10-year survivors of high-grade ovarian cancer, and the role of lymphadenectomy in ovarian cancer peritoneal carcinomatosis. This update also includes current considerations on the role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer peritoneal carcinomatosis as well as relevant ongoing phase III randomized controlled trial protocols.
Highlights
The aim of this update is to bring to light current trends and considerations in the multimodal management of ovarian cancer.1.1
Another study conducted by Zeng et al examined 118 patients with advanced epithelial ovarian cancer (EOC), primary carcinoma of the fallopian tube, and peritoneal carcinoma to determine whether reduction of CA-125 levels is a predictive factor for cytoreduction to no visible residual disease (NVRD) and chemotherapeutic sensitivity [28]
Multivariate analysis showed that a preoperative CA-125 level of equal or less than 200 U/ml was the only independent predictor of NVRD
Summary
The aim of this update is to bring to light current trends and considerations in the multimodal management of ovarian cancer.1.1. The authors concluded that in addition to being an indicator of peritoneal metastasis, positive cytology correlates with capsular invasion and histologic type in ovarian cancer tumors.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
